Verici Dx Plc stock analysis
Want to see GB:VRCI full AI Analyst Report?
Verici Dx Plc (VRCI) Share Price & Analysis
VRCI Stock Chart & Stats
- Day’s Range
- GBX 0.20 - GBX 0.20
- 52-Week Range
- GBX 0.19 - GBX 0.98
- Previous Close
- GBX 0.21
- Volume
- N/A
- Average Volume (3M)
- 17.11M
- Market Cap
- GBP 13.66M
- Enterprise Value
- GBP 4.58M
- Total Cash (Recent Filing)
- GBP 2.41M
- Total Debt (Recent Filing)
- GBP 776.01K
- Price to Earnings (P/E)
- ―
- Beta
- -1.42
- Next Earnings
- Jul 05, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue
The sharp increase in revenue indicates growing commercial adoption of the company’s diagnostic products and expanding market activity. If this trajectory continues, a larger revenue base could improve operating leverage, support broader clinical uptake, and create a stronger platform for future profitability.
Growing Gross Profit
Positive and increasing gross profit shows that the company’s offerings generate value above direct costs as sales expand. This provides an important foundation for improving long-term economics, because continued scale could help absorb fixed research, commercial, and administrative expenses.
Low And Declining Leverage
Low and declining debt reduces the burden of interest and scheduled repayment obligations, while positive equity provides some balance-sheet support. This gives management greater flexibility to pursue development and commercialization without the constraints associated with a highly leveraged capital structure.
Bears Say
Persistent Cash Burn
Continually negative operating and free cash flow means the business is consuming substantial cash to operate and grow rather than funding itself internally. The worsening 2025 burn increases dependence on external financing and could constrain investment or create dilution risk if sustained.
Deepening Net Losses
Persistent operating and net losses show that revenue growth has not yet translated into a sustainable earnings model. The wider 2025 net loss suggests costs remain ahead of commercial scale, potentially delaying profitability and requiring continued funding before the business becomes self-supporting.
Shrinking Asset Base
A materially smaller asset base reduces the financial resources available to support ongoing operations and development. Combined with continuing losses, this may increase reliance on new capital and raises the possibility that future financing could dilute existing shareholders if cash needs remain elevated.
Verici Dx Plc News
VRCI FAQ
What was Verici Dx Plc’s price range in the past 12 months?
What is Verici Dx Plc’s market cap?
When is Verici Dx Plc’s upcoming earnings report date?
How were Verici Dx Plc’s earnings last quarter?
Is Verici Dx Plc overvalued?
Does Verici Dx Plc pay dividends?
What is Verici Dx Plc’s EPS estimate?
How many shares outstanding does Verici Dx Plc have?
What happened to Verici Dx Plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Verici Dx Plc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Verici Dx Plc
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Sara jane Barrington
- Employees
- 23
- Website
- www.vericidx.com
- Address
- Avon House, Cardiff, TN, CF64 2EZ, GB
Verici Dx Plc (VRCI) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 2 | 13 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 1 | 0 | 11 |










